Joseph Evers, MD
Hematology & Oncology · Richmond, VANPI 1649233289
Payments from drug & device makers
Across 105 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$271
- AstraZeneca$236
- Merck$159
- Incyte Corporation$141
- Johnson & Johnson$111
- Pfizer$103
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,12199%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $271 |
| AstraZeneca(2 entities) | 10 | $236 |
| Merck | 8 | $159 |
| Incyte Corporation | 7 | $141 |
| Johnson & Johnson | 5 | $111 |
| Pfizer | 6 | $103 |
| Eisai Inc. | 4 | $96 |
| Ipsen Biopharmaceuticals, Inc | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Novartis | 3 | $72 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Genentech USA, Inc. | 3 | $64 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Beone Medicines USA, Inc. | 2 | $60 |
| Servier Pharmaceuticals LLC | 2 | $49 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 1 | $43 |
| Pharmacosmos Therapeutics Inc. | 2 | $39 |
| Sanofi | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $38 |
| Gilead(2 entities) | 2 | $37 |
| Astellas Pharma US Inc | 2 | $35 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Beigene USA, Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Genmab U.S., Inc. | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $14 |
| Caris MPI, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Seagen Inc. | 1 | $12 |
How this compares
$2,145 in reported general payments places this provider in the 45th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 71 | $1,046,283 |
| PomalystPomalidomide | 48 | $938,785 |
| RevlimidLenalidomide | 38 | $596,934 |
| JakafiRuxolitinib Phosphate | 39 | $455,560 |
| CalquenceAcalabrutinib Maleate | 36 | $426,040 |
| BrukinsaZanubrutinib | 23 | $359,786 |
| Lenalidomide | 12 | $181,416 |
| EliquisApixaban | 86 | $62,815 |
| XareltoRivaroxaban | 31 | $40,866 |
| Abiraterone Acetate | 43 | $6,955 |
| Exemestane | 14 | $4,119 |
| SpsSodium Polystyrene Sulfon/Sorb | 12 | $4,087 |
| Fentanyl | 13 | $3,527 |
| Anagrelide Hcl | 21 | $3,431 |
| Hydroxyurea | 129 | $2,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $44 | $1,046,28371 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $78 | $938,78548 claims |
| Bristol Myers SquibbRevlimid | $14 | $596,93438 claims |
| Incyte CorporationJakafi | $141 | $455,56039 claims |
| AstraZenecaCalquence | $236 | $426,04036 claims |
| Beigene USA, Inc.Brukinsa | $23 | $359,78623 claims |
| PfizerEliquis | $103 | $62,81586 claims |
| Johnson & JohnsonXarelto | $111 | $40,86631 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $43 | $91076 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Richmond
- Erin AlesiRichmond$1.7M
- Sarah GordonRichmond$1M
- Will VoelzkeRichmond$774K
- James KhatcheressianRichmond$773K
- Victor YazbeckRichmond$756K
- William ClarkRichmond$685K
- Elke FriedmanRichmond$571K
- Joshua McFarlaneRichmond$390K
- Jonathan BerkmanRichmond$360K
- Reed MitchellRichmond$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.